ES2819215T5 - Methods of treatment of ocular conditions with a sustained drug delivery implant - Google Patents

Methods of treatment of ocular conditions with a sustained drug delivery implant

Info

Publication number
ES2819215T5
ES2819215T5 ES14805768T ES14805768T ES2819215T5 ES 2819215 T5 ES2819215 T5 ES 2819215T5 ES 14805768 T ES14805768 T ES 14805768T ES 14805768 T ES14805768 T ES 14805768T ES 2819215 T5 ES2819215 T5 ES 2819215T5
Authority
ES
Spain
Prior art keywords
treatment
methods
drug delivery
sustained drug
ocular conditions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14805768T
Other languages
English (en)
Spanish (es)
Other versions
ES2819215T3 (es
Inventor
Jane-Guo Shiah
Rahul Bhagat
Wendy M Blanda
Thierry Nivaggioli
Lin Peng
David Chou
David A Weber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52001114&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2819215(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of ES2819215T3 publication Critical patent/ES2819215T3/es
Application granted granted Critical
Publication of ES2819215T5 publication Critical patent/ES2819215T5/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2031Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204Polyesters, e.g. poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • A61K9/0051Ocular inserts or implants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
ES14805768T 2013-11-15 2014-11-14 Methods of treatment of ocular conditions with a sustained drug delivery implant Active ES2819215T5 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361904887P 2013-11-15 2013-11-15
PCT/US2014/065804 WO2015073895A1 (en) 2013-11-15 2014-11-14 Methods of treatment of ocular conditions with a sustained drug delivery implant

Publications (2)

Publication Number Publication Date
ES2819215T3 ES2819215T3 (es) 2021-04-15
ES2819215T5 true ES2819215T5 (en) 2026-04-01

Family

ID=52001114

Family Applications (1)

Application Number Title Priority Date Filing Date
ES14805768T Active ES2819215T5 (en) 2013-11-15 2014-11-14 Methods of treatment of ocular conditions with a sustained drug delivery implant

Country Status (24)

Country Link
US (2) US20150140062A1 (https=)
EP (2) EP3714875A1 (https=)
JP (2) JP6675307B2 (https=)
KR (3) KR20240058976A (https=)
CN (1) CN105764517A (https=)
AU (4) AU2014348369B2 (https=)
CA (1) CA2929689A1 (https=)
CL (1) CL2016001167A1 (https=)
CY (1) CY1123344T1 (https=)
DK (1) DK3068403T3 (https=)
ES (1) ES2819215T5 (https=)
HU (1) HUE050913T2 (https=)
IL (2) IL245548A0 (https=)
MX (2) MX2016006334A (https=)
MY (1) MY176039A (https=)
NZ (1) NZ719953A (https=)
PH (1) PH12016500869A1 (https=)
PL (1) PL3068403T3 (https=)
PT (1) PT3068403T (https=)
RU (1) RU2690841C1 (https=)
SG (1) SG10201809363SA (https=)
SI (1) SI3068403T1 (https=)
UA (1) UA122117C2 (https=)
WO (1) WO2015073895A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3324944A4 (en) * 2015-07-23 2019-04-03 Aerie Pharmaceuticals, Inc. INTRAVITREAL AGGREGATION SYSTEMS FOR THE TREATMENT OF EYE DISEASE
JP2019534063A (ja) 2016-09-02 2019-11-28 エンビシャ セラピューティクス インコーポレイテッド インプラントアプリケータ
US11690806B2 (en) 2018-05-24 2023-07-04 Celanese Eva Performance Polymers Llc Implantable device for sustained release of a macromolecular drug compound
KR20260007295A (ko) 2018-05-24 2026-01-13 셀라니즈 이브이에이 퍼포먼스 폴리머스 엘엘씨 거대 분자 약물 화합물의 지속적인 방출을 위한 이식가능 장치
US11689849B2 (en) 2018-05-24 2023-06-27 Nureva, Inc. Method, apparatus and computer-readable media to manage semi-constant (persistent) sound sources in microphone pickup/focus zones
CN118718181A (zh) 2019-06-05 2024-10-01 里珍纳龙药品有限公司 用于精确剂量递送的装置及方法
CA3174217A1 (en) * 2020-07-16 2022-01-20 Ocular Therapeutix, Inc. Ocular insert containing a glucocorticoid
BR112023022439A2 (pt) 2021-04-26 2023-12-26 Celanese Eva Performance Polymers Llc Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6726918B1 (en) 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
AU2002236495B2 (en) 2000-11-29 2006-05-11 Allergan, Inc. Intraocular implants for preventing transplant rejection in the eye
US20050048099A1 (en) * 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
US8685435B2 (en) * 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US20050244500A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Intravitreal implants in conjuction with photodynamic therapy to improve vision
US20050244469A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US20090082321A1 (en) * 2007-09-21 2009-03-26 Allergan, Inc. Steroid containing drug delivery systems
CN103402582A (zh) * 2011-02-11 2013-11-20 普西维达公司 使用抗水肿疗法治疗黄斑水肿的方法

Also Published As

Publication number Publication date
AU2024205640A1 (en) 2024-08-29
US20250319031A1 (en) 2025-10-16
AU2020204362A1 (en) 2020-07-23
NZ719953A (en) 2022-01-28
RU2016119132A (ru) 2017-12-20
ES2819215T3 (es) 2021-04-15
AU2014348369B2 (en) 2020-04-02
MY176039A (en) 2020-07-22
CY1123344T1 (el) 2021-12-31
RU2690841C1 (ru) 2019-06-06
SI3068403T1 (sl) 2020-11-30
MX2016006334A (es) 2016-09-06
MX2022002306A (es) 2022-03-25
EP3714875A1 (en) 2020-09-30
EP3068403B1 (en) 2020-06-17
EP3068403B2 (en) 2025-12-03
JP2016538292A (ja) 2016-12-08
HUE050913T2 (hu) 2021-01-28
SG10201809363SA (en) 2018-11-29
JP6675307B2 (ja) 2020-04-01
UA122117C2 (uk) 2020-09-25
KR20160085847A (ko) 2016-07-18
PH12016500869B1 (en) 2016-07-04
US20150140062A1 (en) 2015-05-21
DK3068403T3 (da) 2020-09-07
WO2015073895A1 (en) 2015-05-21
KR20220082934A (ko) 2022-06-17
CL2016001167A1 (es) 2017-01-06
CA2929689A1 (en) 2015-05-21
KR102475746B1 (ko) 2022-12-08
JP2020055862A (ja) 2020-04-09
CN105764517A (zh) 2016-07-13
KR20240058976A (ko) 2024-05-07
PH12016500869A1 (en) 2016-07-04
IL290837A (en) 2022-04-01
AU2024205640B2 (en) 2025-10-23
EP3068403A1 (en) 2016-09-21
PL3068403T3 (pl) 2021-01-11
AU2022204607A1 (en) 2022-07-21
PT3068403T (pt) 2020-09-18
JP7022735B2 (ja) 2022-02-18
IL245548A0 (en) 2016-06-30
AU2014348369A1 (en) 2016-06-09

Similar Documents

Publication Publication Date Title
IL290837A (en) Methods for the treatment of ocular diseases using a continuous drug delivery implant
IL244259A0 (en) Insertion of medical devices
EP2838511A4 (en) OCULAR MEDICATION DELIVERY SYSTEM
ZA201405898B (en) Devices for targeted delivery of therapeutic implants
PT2648663E (pt) Dispositivo para administração por iontoforese de riboflavina na córnea para o tratamento de queratocone
IL262062A (en) Implantable ophthalmic drug delivery devices
ES3062283T3 (en) Drug delivery devices and methods for drug delivery
HUE072250T2 (hu) Gyógyszeradagoló eszközök gyógyszeráteresztõ résszel
EP2908874A4 (en) MEDICAL ACTIVE COMPOSITION DEVICE
EP2768430A4 (en) CORNEAL IMPLANT STORAGE AND INSTALLATION DEVICES
EP3183026A4 (en) Implants for localized drug delivery and methods of use thereof
SG11201502274XA (en) A device for a medical treatment of a sclera
PL3073936T3 (pl) Wszczep medyczny
PL3413872T3 (pl) Nieinwazyjna wkładkowa technologia podawania leków do oka
IL242760B (en) A Biomimetic Peptide and Biodegradable Delivery Platform for the Treatment of Angiogenesis and Lymphangiogenesis-Dependent Diseases
EP2893903A4 (en) IMPLANTABLE DEVICE FOR MOLDING THE CORD BEND
HUE046600T2 (hu) Biológiailag lebomló ötvözeteket tartalmazó beültethetõ gyógyászati eszközök javított lebomlási sebességgel
ZA201403767B (en) Implantable drug delivery compositions and methods of treatment
PL2959903T3 (pl) Lek do leczenia chorób oczu
IL232460A0 (en) A biologically compatible implantable electorada
GB201721832D0 (en) Ocular drug delivery
PL2556806T3 (pl) Wszczepialna proteza medyczna
GB201316738D0 (en) Implantable Medical Devices
GB201319437D0 (en) Delivery of drugs
IL245983A0 (en) Biologically active insulin derivatives